Fucoidan / PD-L1 Cancer Research Results

F, Fucoidan: Click to Expand ⟱
Features:
Fucoidan is found in brown algae. Extracted from the seaweed species Fucus vesiculosus, Cladosiphon okamuranus, Laminaria japonica and Undaria pinnatifida.
In oncology research, fucoidan is most consistently described as an immunomodulatory and anti-angiogenic compound with additional pro-apoptotic and anti-metastatic effects in preclinical models. Mechanistically, fucoidan has been reported to suppress NF-κB and PI3K/AKT signaling, reduce VEGF-mediated angiogenesis, inhibit tumor cell adhesion and invasion, and promote apoptosis through caspase activation and mitochondrial pathways. It may also enhance NK cell and macrophage activity, contributing to anti-tumor immune responses. Effects vary substantially depending on molecular weight, sulfation pattern, and source species. Human clinical data remain limited, and many anticancer claims are derived from in vitro and animal studies.


Cancer Pathway Table: Fucoidan

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 Immune activation (NK cells / macrophages) NK activity ↑; macrophage activation ↑ (reported) Immune surveillance support R, G Immunostimulatory One of the most consistent themes; fucoidan enhances innate immune responses in tumor-bearing animal models.
2 NF-κB inflammatory / survival signaling NF-κB ↓; cytokines ↓ (reported) Inflammatory tone modulation R, G Anti-inflammatory / anti-survival Suppression of NF-κB contributes to reduced tumor-promoting inflammation and survival signaling.
3 PI3K → AKT signaling PI3K/AKT ↓; proliferation ↓ (model-dependent) ↔ R, G Growth signaling suppression Reported in multiple cancer cell models; often secondary to upstream immune or redox modulation.
4 Intrinsic apoptosis (mitochondrial pathway) Caspases ↑; Bax ↑; Bcl-2 ↓ (reported) Minimal apoptosis in normal cells (dose-dependent) G Apoptotic induction Apoptosis frequently reported in vitro; magnitude depends on molecular weight and sulfation.
5 Angiogenesis (VEGF signaling) VEGF ↓; angiogenesis ↓ (reported) ↔ G Anti-angiogenic Anti-angiogenic activity is one of the more reproducible findings in preclinical systems.
6 Metastasis / adhesion (selectins, ECM interaction) Tumor adhesion ↓; invasion ↓ (reported) ↔ G Anti-metastatic Sulfated structure may interfere with selectin-mediated adhesion and tumor cell migration.
7 ROS / redox modulation ROS modulation (context-dependent) Antioxidant protection reported P, R Redox modulation (secondary) Fucoidan is not a primary pro-oxidant; redox effects appear secondary to signaling changes.
8 Chemo / radiation synergy Sensitization ↑ (reported in models) ↔ G Adjunct potential May enhance cytotoxic therapy response; evidence largely preclinical.
9 Warburg metabolism Indirect modulation (not a primary glycolysis inhibitor) ↔ R Metabolic secondary effect Metabolic changes likely downstream of survival pathway suppression rather than direct glycolysis blockade.
10 Bioavailability / heterogeneity constraint Effects vary by molecular weight and source Generally well tolerated orally — Translation constraint Composition varies widely by seaweed species and extraction method; standardization is critical.

TSF: P = 0–30 min (surface receptor interactions), R = 30 min–3 hr (immune and signaling shifts), G = >3 hr (apoptosis, angiogenesis, immune outcomes).



PD-L1, Programmed Death-Ligand 1: Click to Expand ⟱
Source:
Type:
PD-L1 is a protein that plays a crucial role in the regulation of the immune system. PD-L1 helps to prevent the immune system from attacking healthy cells by binding to its receptor, PD-1, on immune cells. However, some cancer cells can exploit this mechanism by expressing high levels of PD-L1, which can help them evade immune detection.
PD-L1 has become a key target for cancer immunotherapy, particularly in the development of checkpoint inhibitors.

PD-1: Upregulated on tumor-infiltrating lymphocytes (TILs), reflecting chronic antigen exposure and an “exhausted” T cell phenotype.
PD-L1 and PD-L2: Frequently overexpressed by many tumor types (e.g., non–small cell lung cancer, melanoma, renal cell carcinoma, head and neck cancers.
Scientific Papers found: Click to Expand⟱
1039- F,    Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network
- in-vitro, NA, NA
TumCP↓, Apoptosis↑, PD-L1↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death ⓘ

Apoptosis↑, 1,  

Migration ⓘ

TumCP↓, 1,  

Immune & Inflammatory Signaling ⓘ

PD-L1↓, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: PD-L1, Programmed Death-Ligand 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:81  Target#:243  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page